Floatz logo

ALLOGENEIC, EX VIVO EXPANDED, UMBILICAL CORD BLOOD-DERIVED HEMATOPOIETIC CD133+ PROGENITOR CELLS- CULTURED FRACTION (CF)

Hematological Malignancies

Gamida Cell ltdCell therapyPhase 3Dormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
95/ 100

Competitive context

137 Active assets in the Hematological Malignancies cohort.

Asset / SponsorPhaseRating
Inno-206
OHSU Knight Cancer Institute
Phase 4BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 3BBB
Teclistamab
Janssen Pharmaceutical K.K.
Phase 2BB
DEXAMETHASONE
City of Hope Medical Center
Phase 3BB
Bortezomib
OHSU Knight Cancer Institute
Phase 4BB

View all 50 →

Same molecule, other indications

ALLOGENEIC, EX VIVO EXPANDED, UMBILICAL CORD BLOOD-DERIVED HEMATOPOIETIC CD133+ PROGENITOR CELLS- CULTURED FRACTION (CF) is also rated in:

acute myeloid leukemiaDormant
BB
Indicative ·
69 / 100
View asset →
myelodysplastic syndromeDormant
BB
Indicative ·
69 / 100
View asset →
acute lymphoblastic leukemiaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →